IN2014DN10288A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10288A
IN2014DN10288A IN10288DEN2014A IN2014DN10288A IN 2014DN10288 A IN2014DN10288 A IN 2014DN10288A IN 10288DEN2014 A IN10288DEN2014 A IN 10288DEN2014A IN 2014DN10288 A IN2014DN10288 A IN 2014DN10288A
Authority
IN
India
Prior art keywords
present
epitope peptides
mutants
relates
recombinant proteins
Prior art date
Application number
Inventor
Quan Yuan
Tianying Zhang
Wenxin Luo
Yixin Chen
Jun Zhang
Ningshao Xia
Original Assignee
Univ Xiamen
Xiamen Innovax Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Xiamen, Xiamen Innovax Biotech Co Ltd filed Critical Univ Xiamen
Publication of IN2014DN10288A publication Critical patent/IN2014DN10288A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides cell lines producing said antibodies and uses thereof. Furthermore the present invention relates to vaccines or pharmaceutical compositions for treating or alleviating one or more symptoms relating to hepatitis B virus infection which respectively comprise recombinant proteins or antibodies in the present invention.
IN10288DEN2014 2012-06-11 2013-06-06 IN2014DN10288A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210190329 2012-06-11
PCT/CN2013/076832 WO2013185558A1 (en) 2012-06-11 2013-06-06 Polypeptides and antibodies for treating hbv infection and related diseases

Publications (1)

Publication Number Publication Date
IN2014DN10288A true IN2014DN10288A (en) 2015-08-07

Family

ID=49757513

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10288DEN2014 IN2014DN10288A (en) 2012-06-11 2013-06-06

Country Status (12)

Country Link
US (2) US9751914B2 (en)
EP (2) EP2860188B1 (en)
JP (1) JP6440259B2 (en)
KR (2) KR101944263B1 (en)
CN (2) CN103483421B (en)
AU (1) AU2013276015B2 (en)
BR (2) BR122020023349B1 (en)
CA (2) CA2876020C (en)
ES (2) ES2834072T3 (en)
HK (1) HK1203978A1 (en)
IN (1) IN2014DN10288A (en)
WO (1) WO2013185558A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122020023349B1 (en) * 2012-06-11 2023-02-07 Xiamen University MONOCLONAL ANTIBODY, HYBRIDOMA CELL LINE, KIT AND USE OF THE MONOCLONAL ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT THEREOF
CN107001429B (en) * 2014-11-28 2022-01-04 赛特瑞恩股份有限公司 Epitope of hepatitis B virus surface antigen and binding molecule specifically binding thereto for neutralizing hepatitis B virus
CA3001231C (en) 2015-10-09 2022-07-12 Xiamen University Antibody against hepatitis b surface antigen and use thereof
WO2018064602A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
CN108456686B (en) 2017-02-17 2021-03-05 厦门大学 Polypeptide carrier for displaying target polypeptide and application thereof
WO2018184593A1 (en) * 2017-04-07 2018-10-11 厦门大学 Antibody for treating hepatitis b infection and related disease
CN109718364A (en) * 2017-10-27 2019-05-07 上海贺普药业股份有限公司 The drug and method of hepatitis B related liver disease are treated under the conditions of full dose
US11932681B2 (en) * 2018-05-31 2024-03-19 Novartis Ag Hepatitis B antibodies
KR102084912B1 (en) * 2019-01-17 2020-03-05 주식회사 녹십자 Conformational epitope of hepatitis b virus surface antigen and antibody specifically binding to the same
GB201904328D0 (en) * 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
WO2020233715A1 (en) * 2019-05-23 2020-11-26 厦门大学 Anti-hepatitis b virus antibodies and use thereof
BR112022005687A2 (en) 2019-09-30 2022-06-21 Gilead Sciences Inc Vaccines against hbv and methods to treat hbv
CN111187349A (en) * 2019-10-30 2020-05-22 四川迈克生物新材料技术有限公司 Method for preparing monoclonal antibody
CN113138276B (en) * 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 Method for detecting HBcAg and antibody
CN113717283B (en) * 2020-05-25 2023-05-26 厦门万泰凯瑞生物技术有限公司 Monoclonal antibody for resisting hepatitis B virus e antigen and application thereof
CN111879932B (en) * 2020-06-24 2022-09-27 南方医科大学南方医院 Hepatitis B Virus (HBV) specific B cell epitope detection method and application thereof
CN113234143B (en) * 2021-05-10 2021-12-14 合肥金域医学检验实验室有限公司 Nucleic acid antibody kit for rapidly detecting virus
CN114671947B (en) * 2022-02-28 2024-04-09 中国科学院生物物理研究所 High-affinity nano antibody for surface S protein of different subtypes of hepatitis B virus and application thereof
CN116162153A (en) * 2022-09-01 2023-05-26 复旦大学附属中山医院 Monoclonal antibody of hepatitis B virus surface antigen and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
WO1985004103A1 (en) * 1984-03-09 1985-09-26 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell anc b cell determinants
US20110097352A9 (en) 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
JP2000514643A (en) * 1996-04-18 2000-11-07 アボツト・ラボラトリーズ Antigenic epitope of a-determinant of hepatitis B surface antigen and its use
ATE324448T1 (en) * 1999-10-08 2006-05-15 Celltech Pharma Europ Ltd DESIGNED BY IMMUNOGENE
EP1461423B1 (en) 2001-12-03 2008-05-14 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
JP4948783B2 (en) * 2005-05-18 2012-06-06 シスメックス株式会社 Anti-HBs monoclonal antibody
CN101606066A (en) * 2006-10-30 2009-12-16 株式会社先端生命科学研究所 The analytical approach of hepatitis b virus s antigen
CN101748129A (en) * 2008-12-04 2010-06-23 上海裕隆临床检验中心有限公司 Preparation method of anthropogenic hepatitis B virus surface antibody
BR122020023349B1 (en) * 2012-06-11 2023-02-07 Xiamen University MONOCLONAL ANTIBODY, HYBRIDOMA CELL LINE, KIT AND USE OF THE MONOCLONAL ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT THEREOF

Also Published As

Publication number Publication date
JP2015522563A (en) 2015-08-06
CN103483421B (en) 2019-10-22
BR112014030797A2 (en) 2017-07-25
HK1203978A1 (en) 2015-11-06
EP3308798B1 (en) 2020-09-09
CA2876020C (en) 2018-08-21
ES2843675T3 (en) 2021-07-20
US10246494B2 (en) 2019-04-02
CA2943258A1 (en) 2013-12-19
JP6440259B2 (en) 2018-12-19
US9751914B2 (en) 2017-09-05
EP2860188A4 (en) 2016-04-27
EP3308798A3 (en) 2018-05-30
CA2943258C (en) 2020-12-22
EP2860188B1 (en) 2020-10-21
CN103483421A (en) 2014-01-01
AU2013276015A1 (en) 2014-12-18
US20180002382A1 (en) 2018-01-04
AU2013276015B2 (en) 2017-04-20
BR122020023349B1 (en) 2023-02-07
WO2013185558A1 (en) 2013-12-19
US20150246948A1 (en) 2015-09-03
KR101944263B1 (en) 2019-02-01
KR20150043289A (en) 2015-04-22
KR102106782B1 (en) 2020-05-07
ES2834072T3 (en) 2021-06-16
EP2860188A1 (en) 2015-04-15
CN106046155B (en) 2019-11-22
CN106046155A (en) 2016-10-26
CA2876020A1 (en) 2013-12-19
EP3308798A2 (en) 2018-04-18
KR20190011247A (en) 2019-02-01

Similar Documents

Publication Publication Date Title
IN2014DN10288A (en)
PH12017501287A1 (en) A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
WO2014139476A8 (en) Epitope of rsv fusion protein and antibody identifying same
MX2019003716A (en) Pharmaceutical formulations of tnf-alpha antibodies.
MX2015008847A (en) Influenza virus immunogenic compositions and uses thereof.
IN2014KN01713A (en)
IN2014KN01714A (en)
IN2014KN01716A (en)
EA201391170A1 (en) THERAPEUTIC MEANS BASED ON YEAST FOR THE TREATMENT OF CHRONIC HEPATITIS B
MX2016004063A (en) Pcv2 orf2 protein variant and virus like particles composed thereof.
GB2513768A (en) Complexes of cytomegalovirus proteins
NZ761006A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
MX360368B (en) Modified antibody regions and uses thereof.
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
NZ602548A (en) Oligomer-specific amyloid beta epitope and antibodies
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
MX2016012840A (en) Improved modular antigen transportation molecules and uses therof.
WO2012139106A3 (en) Herpes simplex virus
IN2014DN09445A (en)
MX358507B (en) Chimeric vaccine antigens against hepatitis c virus.
CL2021001479A1 (en) peptide; use of compositions; pharmaceutical composition; use of an antibody for therapy; use of an antibody for elisa, immunohistochemistry and/or imaging; t cell receptor; and use of an activated cytotoxic t-lymphocyte (divisional of application no. 201701391)
MX2019007924A (en) Influenza vaccines.
MX2015016670A (en) Process for preparing apolipoprotein a-i (apo a-i).
IN2015DN02772A (en)
GB201118201D0 (en) Novel peptides